This judgment arose inside a larger patent revocation proceeding. Abbey Laboratories was seeking to revoke a patent owned by Virbac concerning formulations for the topical treatment of cattle for parasites. Abbey's pleaded grounds included novelty and lack of inventive step.
The immediate issue before the Court was much narrower. It was not a final ruling on patent validity. Instead, it was an interlocutory fight about whether Abbey had to comply with a notice to produce served by Virbac shortly before the hearing.
Abbey had relied on expert evidence from Dr Fadil Alawi, a veterinary pharmaceutical formulator. In his affidavit, Dr Alawi explained his consulting work through Pharminnovation Ltd and disclosed that Pharminnovation had been retained by Abbey on approximately 5 to 9 animal health product development projects since April 2019, with the most recent ending in June 2022.
Virbac then sought documents about each of those projects. The request was broad. It sought documents sufficient to identify active ingredients, excipients including solvents, method of administration and target animal, and also documents recording the name of any registered animal health product resulting from a project.
That request was important because it reached beyond the immediate patent subject matter. The Court specifically noted that the notice was not confined to projects involving formulations for the topical treatment of cattle for parasites. Abbey therefore applied for an order dispensing with compliance.